Mostrando entradas con la etiqueta fertility treatment. Mostrar todas las entradas
Mostrando entradas con la etiqueta fertility treatment. Mostrar todas las entradas

viernes, 8 de febrero de 2013

Mehr Fernsehen macht weniger Spermien


Um 44 Prozent reduziert - Es kommt auf die körperliche Bewegung an
Mehr als 20 Stunden vor dem Fernseher pro Woche lässt bei 18- bis 22-jährigen Männern die Zahl der Spermien im Vergleich zu Altersgenossen mit geringer Zeit vor dem Bildschirm um 44 Prozent sinken. Umgekehrt treiben mehr als 15 Stunden moderaten bis intensiven Ausgleichssport bei Männern die Spermienanzahl um 73 Prozent in die Höhe - im Vergleich zu solchen, die sehr wenig Sport betreiben. Diese Ergebnisse haben US-Forscher im "British Medical Journal" veröffentlicht.
Untersucht wurden in der Studie 189 Männer aus Rochester im US-Staat New York. Es ging in der Studie von Audrey Jane Gaskins und Jorge Chavarro von der Harvard School of Public Health (Boston) um die Bestimmung des Einflusses eines sitzenden Lebensstils bei gesunden jungen Männern auf die Spermienqualität.

Je nach TV-, DVD- oder Videokonsum bzw. je nach dem zeitlichen Engagement beim Sport zeigten sich die Veränderungen bei der Zahl der Spermien, nicht aber bei ihrer Beweglichkeit und bei anderen Kriterien. Eine geringere Spermienzahl muss nicht unbedingt eine Einschränkung der Fertilität bedeuten. Mehr als die Hälfte der Probanden hatte Normalgewicht, drei Viertel waren Nichtraucher. (tha)

Quelle: British Medical Journal


lunes, 1 de octubre de 2012

New communication service to GENIPLET patients


Our treatments are highly indivdual and require constant direct contact between the International Department, e.g.  Dimitrina Lisichkova, your attending physician and you as a patient. We will need ready access to you. Often during the preparation and treatment rapid  and urgent decisions are required. We therefore collect all available telephone numbers, email addresses, Skype, WhatsApp, SMS etc.

Please ensure that you are always reachable.
The communication contains medical information and treatment instructions. This must be documented in your electronic file. This requires that we focus on Telephone / Skype and email. These are automatically stored in your file. Other means of communication are not well suited for it, and should be used only in exceptional cases.

Full telephone calls should be kept always by appointment not to disturb our work and talking with other patients. Announce this please always with Dimitrina.

If you are overseas, it is imperative that we reach you by mail. So you should create a way to have access to the email account known to us. This is uncompfortable when using the local SIM cards due to overpriced roaming charges. It is recommended that  You buy in each country a prepaid - SIM card with a flat rate for data traffic.

Once you are in Mallorca we can recommend a partner who hires You a small portable wireless  router. You can book in advance on our and his website. He will then deliver it to the clinic for you. It and can be used during your stay with an affordable flat rate with costs from 5.70 to 10 € per day at any time with Internet availability for all WLAN - establish appropriate devices. These are for example Smartphones (eg iPhone) or laptops and tablets (eg iPad). You can use VOIP like Skype etc. quite normal. So you can leave the expensive roaming function of your devices turned off and get reached for us as well as for your personal or business contacts at any time via email or Skype.

Before departure bring WIFIrental router back at us. Book before you travel or even if you already here on the island, by putting in. Use our promotional code, you will get 5% discount on the offer price. The payment to be settled directly with the company WIFIrental Travel (www.wifirental.travel).

We have agreed with the seller for a discount of 5% off for our patients at the normal price.

martes, 25 de septiembre de 2012

EU-Parlament: Zell- und Gewebespenden nicht kommerzialisieren




The plenary session of the European Parliament adopted by 551 votes to 14, with 81 abstentions, a ban of financial incentives for cell donation: also sperm and egg. Only a cost replacement for lost work time and other expenses should be allowed. Basically, this is already in place in Spain since 1985. The problem is centered about the anonymity. The EU has a strict aim of banning the donors anonymity.
This was realized in England many years ago. The result has been disastrous. Hence, in England there are almost no more fresh or frozen donor eggs. Nobody wants to get into the risk of being outed. This risk has compensated by money. It benefits no one, if the pure doctrine is guideline, but donation is not longer available for all and everybody has to travel abroad. Another problem is that: in countries with high wage level, the cost reimbursement is not sufficient enough to motivate young women, for this there is a serious interference with their physical integrity, including all the related emotional stress. For Spain, on the contrary with its relatively low wages, may be enough.

This must be separated with organ donations that serve the preservation of life and, those that create a new life. Much higher is the concern of top healthy gamete donors. No question, if you're not a pay deceased organ donor and his descendants. Or, possibly, even the executive organ donation, the donor organizations and their doctors.

In the gametes cells (i.e., egg and sperm) which produce the genetic offspring of a donor, their personal involvement is much higher and for that also be reimbursed. Because it can have clear adversely affect on health and in social coexistence for donors during their ongoing life. Mr. Liege, a German politician in Brussels, who has sometimes shown an interest in the health and well-being (and proposed this Act in the Parliament), and he simply has not thought enough.
If the EU continues on this wrong path, both remove the anonymity from prohibiting the compensation for services, and on the correction of a completely out of control current demographic structure, this service will move to non-European regions. In that way, such as in Spain, the legal certainty will be lost, and it becomes more expensive. In any case, the rich will certainly get some benefit from this method.
What is lacking in the political process of sufficient research and consulting. There is another example of the increasingly poor quality of political work. Spain can be proud of its parliament that in 1985 approved the current reproductive law, shortly after the end of dictatorship.
In any case and in any time, the Geniplet Group can already offer outside the EU, egg and sperm donation with the usual high quality without being exposed to the European regulatory frenzy. We are committed exclusively to the quality in the interest of our patients and our overarching ethical principles. Of course, we strictly observe the legal regulations of the different countries, although they might be nonsensical.




Dr.P.Hermann
Medical Director
Geniplet Palma Reproductive Clinic

Das Plenum des Europäischen Parlaments hat mit 551 gegen 15 Stimmen bei 81 Enthaltungen ein Verbot der Zellspende, auch Samen und Eizellen, gegen Honorar empfohlen. Es soll lediglich ein Kostenersatz für entgangene Arbeitszeit und sonstige Unkosten zulässig sein.
Im Grunde ist dies in Spanien bereits so eingeführt.
Das Problem liegt aber in der Anonymität. Die EU hat das strikte Ziel, die Anonymität der Spende zu verbieten. Dies wurde in England vor vielen Jahren verwirklicht. Die Folge davon ist fatal. Es gibt in England seither fast keine frischen Eizellspenden mehr. Niemand will sich in die Gefahr bringen, geoutet zu werden. Dieses Risiko muss erkauft werden. Es nützt niemandem, wenn zwar die reine Lehre verfolgt wird, die Spende aber damit nicht mehr verfügbar wird und nahezu alle, die sie benötigen, ins Ausland reisen müssen. 

Ein weiteres Problem ist, dass in Ländern mit hohem Lohn-Niveau ein reiner Kostenersatz nicht ausreicht, um genügend junge Frauen zu diesem schweren Eingriff in ihre körperliche Integrität samt all den damit zusammenhängenden emotionalen Belastungen, zu motivieren. Für Spanien mit seinen relativ niedrigen Löhnen mag das ausreichen.

Es muss auch strikt getrennt werden zwischen Organ - Spenden, welche dem Erhalt von bestehendem Leben dienen , und solchen Spenden, welche neues Leben erzeugen. Ungleich höher ist die Betroffenheit der ja top - gesunden Gametenspender. Keine Frage, dass man einen verstorbenen Organspender und seine Nachfahren nicht bezahlen soll. Möglicherweise auch nicht die ausführenden Organe einer Organspende, Organisationen und Ärzte. 
Bei Gameten, Eizellen und Samenzellen, welche genetische Nachkommen der Spender erzeugen, ist die persönliche Betroffenheit der Spender ungleich höher und damit auch zu vergüten. Denn selbstverständlich können sich nachteilige Auswirkungen gesundheitlich und auch im sozialen Zusammenleben für die Spender ergeben. Herr Liese, ansonsten ein kenntnisreicher guter Gesundheitspolitiker aus Deutschland in Brüssel, hat hier einfach nicht zu Ende gedacht.
Falls die EU also auf diesem falschen Weg weiter voranschreitet, sowohl die Anonymität aufzuheben als auch die Entschädigung für den Dienst an der Korrektur einer völlig aus dem Ruder laufenden demographischen Struktur zu verbieten, wird sich dieser Service ins aussereuropäische Umland verlagern. Damit geht die Rechtssicherheit wie z.B. in Spanien verloren, es wird teurer und die Methode steht nur mehr den leistungsfähigeren Bevölkerungsschichten zur Verfügung.
Hier fehlt es im politischen Prozess an ausreichender Recherche und Beratung. Ein weiteres Beispiel für die zunehmend schlechtere Qualität politischer Arbeit. Spanien kann stolz sein auf sein Parlament welches das aktuelle Reproduktions-Gesetz 1985, kurz nach Ende der Diktatur, auf den Weg gebracht hat.
GENIPLET jedenfalls hat sich darauf eingerichtet und kann bereits jetzt  jederzeit auch ausserhalb der EU Eizellspenden und Samenspenden mit der gewohnt hohen Qualität anbieten ohne der Europäischen Regelungswut ausgesetzt zu sein. Wir sind ausschliesslich der Qualität im Interesse unserer Patienten und unseren übergeordneten ethischen Grundsätzen verpflichtet. Selbstverständlich beachten wir die gesetzlichen Regelungen in den einzelnen Ländern streng, so unsinnig sie auch sein mögen.

Dr.P.Hermann
Medical Director
Geniplet Palma Reproductive Clinic


La sessione plenaria del Parlamento europeo ha approvato con 551 voti favorevoli contro 14, e 81 astensioni, il divieto di incentivi finanziari per la donazione di cellule: sperma e uova. Potranno essere consentiti solamente i costi per il lavoro perso e altre spese affini. In pratica, tutto ciò è già in vigore in Spagna dal 1985. Tuttavia, il punto focale riguarda l'anonimato. L'Unione Europea ha come chiaro obiettivo vietare l’anonimato per i donatori.
Questo è stato effettuato in Inghilterra molti anni fa e il risultato è stato disastroso. Infatti, in Inghilterra non ci sono quasi più ovuli freschi o surgelati. Nessuno vuole correre il rischio di uscire dall’anonimato ed è per questo, che il rischio dovrebbe essere compensato in denaro. Non giova a nessuno, se la pura teoria verrà usata come linea guida, di certo, la donazione non sarà più accessibile a tutti e quindi si dovrà viaggiare all'estero. Un altro problema è che nei Paesi con un alto tasso salariale, il rimborso dei costi non è sufficiente a motivare le giovani donne, dato che questo processo implica una grave interferenca nella loro integrità fisica, e un correlato forte stress emotivo. Al contrario in Spagna, con i suoi salari relativamente bassi, il rimborso dei costi potrebbe essere sufficiente.
Si devono tenere separate dalle donazioni di organi, quelle che servono a preservare a vita da quelle che servono a crearne una nuova. Maggiore poi è la preoccupazione per i donatori sani di gameti. Non c’è nessuna alternativa, se non sei un donatore (pagante) di organi deceduto o uno dei suoi discendenti. O, possibilmente, nemmeno la donazione di organizi esecutiva, le organizzazioni di donatori e relativi medici.
Se l'Unione Europea continuerà su questa strada sbagliata, togliendo l'anonimato per i donatori e vietando la compensazione il servizio, per correggere l’attuale struttura demografica completamente fuori controllo, questo tipo di servizio si sposterà verso aree non europee. In questo modo, come ad esempio per la Spagna, la certezza del diritto verrà perduta, e il tutto diventerà più costoso. In ogni caso, le persone ricche saranno certamente le uniche che otterranno qualche beneficio da questa situazione.
Quello che manca nel processo politico è una ricerca e una consulenza adeguata. Questo è un altro esempio della sempre peggiore qualità del lavoro politico. La Spagna può essere orgogliosa del proprio parlamento che nel 1985, poco dopo la fine della dittatura, approvò la sua attuale legge sulla riproduzione.In ogni caso e in qualsiasi momento, il Gruppo Geniplet può già offrire, al di fuori dell'UE, la donazione di ovuli e di sperma con la sua consueta ed elevata qualità senza essere esposto alla frenesia normativa europea. Ci dedichiamo esclusivamente alla ricerca della qualità nell'interesse dei nostri pazienti e rispettanto i nostri solidi principi etici. Naturalmente, osserviamo pedisequamente le disposizioni normative dei diversi Paesi, anche se potrebbero essere prive di senso.
Nelle cellule di gameti (cioè, uova e sperma) che portano alla nascita la prole genetica di un donatore, il loro coinvolgimento personale è molto più alto e anche per questo lo sarà anche il rimborso. Perché potrebbe avere un chiaro effetto negativo sulla loro salute e può coesistere socialmente con i donatori durante il corso della loro vita. Il sig. Liese, un politico tedesco a Bruxelles, che ha altre volte mostrato un interesse per la salute e il benessere (e ha proposto questo al in Parlamento), semplicemente non ci ha riflettuto abbastanza.


Dr.P.Hermann
Medical Director
Geniplet Palma Reproductive Clinic

lunes, 30 de julio de 2012

IVF drugs may reduce breast cancer risk if fertility treatment unsuccessful.
Progress Educational Trust
29 July 2012


[BioNews, London]


Women who undergo fertility treatment but do not become pregnant have a reduced risk of developing breast cancer before the age of 50, according to scientists.
The research, conducted at the National Institutes of Health in the USA, found the risk was slightly reduced in women treated with ovulation-stimulating fertility drugs. Women who went on to have a pregnancy lasting for ten weeks or longer, however, had a significantly higher risk compared to those for whom treatment was unsuccessful. This increased risk was comparable to that of women who have never received fertility treatment, suggesting that pregnancy reverses the protection provided by the fertility drugs.
'I don't see the results as any cause for alarm. But everyone needs to manage their risk and be careful', lead researcher Dr Clarice Weinberg, from the National Institute of Environmental Health Sciences, said.
Dr Marcelle Cedars, a reproductive endocrinologist from the University of California who was not involved in the study, added: 'Even in the group at an increased risk after their pregnancy, their risk was not higher than the general public. If you use fertility drugs, you're not increasing your risk'.
The researchers followed 1,400 women who had been diagnosed with breast cancer before the age of 50, along with 1,600 of their sisters who had never had breast cancer. Of these women, 288 reported using ovulation-stimulating fertility drugs, with 141 going on to conceive a pregnancy lasting for ten or more weeks. Those who received treatment but did not become pregnant had a significantly reduced risk of young-onset breast cancer compared to those who did go on to conceive.
Ovulation-stimulating drugs increase the production of oestrogen - a hormone that has previously been linked to breast cancer. Oestrogen levels gradually return to normal in women who do not become pregnant, but remain high in those who do and may affect breast tissue remodelling during pregnancy.
Dr Louise Brinton, chief of hormonal reproductive epidemiology at the National Cancer Institute, believes that the choice of fertility drug - most of the women in the study were treated with clomiphene, which belongs to the same family as the chemotherapy drug tamoxifen - explains the reduction in breast cancer risk.
The research is published in the Journal of the National Cancer Institute.